News

Semaglutide injections have surprising benefits for liver disease patients, study shows
Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine.
Greek Reporter1d
Landmark Study Finds Wegovy, Ozempic, Effectively Treat Serious Liver Disease
A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...
Active ingredient in weight loss drug Wegovy may help treat fatty liver disease
The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...
Managed Healthcare Executive1d
FDA Sets Action Date for Oral Wegovy for Weight Loss
A decision is expected in the fourth quarter of 2025.
Novo Nordisk says oral version of Wegovy accepted for FDA review
Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.
Why Is Novo Nordisk Stock Trading Higher On Friday?
Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...
UNILAD1d
Doctor explains 'safety confusion' over Ozempic-like medication after conflicting studies released
Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...
Becker's Hospital Review1d
CVS Caremark selects Wegovy as preferred GLP-1 for commercial formularies
CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...
Where Will Viking Therapeutics Be in 3 Years?
Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.